Meeting
2020 ASCO Virtual Scientific Program
Safety and efficacy of gemtuzumab ozogamicin and venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: A phase Ib study.
Authors
Saad Arain
UIC, Chicago, IL
Saad Arain , Sonia Christian , Pritesh Rajni Patel , Karen Sweiss , Brian Parkin , Gregory Sampang Calip , John G Quigley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04070768
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS7566)
DOI
10.1200/JCO.2020.38.15_suppl.TPS7566
Abstract #
TPS7566
Poster Bd #
339
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Preclinical evaluation of the ETS inhibitor TK216 against relapsed and refractory childhood leukemia.
First Author: Ritul Sharma
Poster
2018 ASCO Annual Meeting
A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.
First Author: Orlando Bueno
Poster
2017 ASCO Annual Meeting
Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.
First Author: Maria-Victoria Mateos
Poster
2015 ASCO Annual Meeting
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
First Author: Shaji Kumar